Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Remimazolam Compared With Midazolam During Bronchoscopy:Randomised Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged ≥18 years who required diagnostic or therapeutic bronchoscopy and agreed to participate~Exclusion Criteria:~* 1) pregnancy, 2) moderate-to-severe hepatic impairment and lactose intolerance 3) mechanical ventilation 4) history of tracheostomy 5) poor patient cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: EXPERIMENTAL): Patients aged \<60 years or weighing \>50 kg were randomly assigned to receive 3 mg intravenous midazolam. In contrast, those aged ≥60 years or with a body weight of \<50 kg were assigned 2 mg intravenous.~If adequate sedation was not achieved after the initial sedative administration, additional midazolam (0.5 mg) was administered at intervals of 3-4 min, at the discretion of the physician.
- Remimazolam (Type: ACTIVE_COMPARATOR): Patients aged \<60 years or weighing \>50 kg were randomly assigned to receive 5 mg remimazolam. In contrast, those aged ≥60 years or with a body weight of \<50 kg were assigned intravenous 3 mg remimazolam.~If adequate sedation was not achieved after the initial sedative administration, additional remimazolam (2.5 mg) was administered at intervals of 3-4 min, at the discretion of the physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).